10-Q: Charlies Holdings Reports Q3 Profit Amid Asset Sale & SBX Growth

Charlies Holdings, Inc. reported a significant net income for Q3 2025, driven by a $7.5 million asset sale and strong early sales of its new SBX Metatine vape products, despite ongoing regulatory challenges and a 'going concern' warning.

Summary

• Reported net income of $624,000 for the three months ended September 30, 2025, a substantial improvement from a net loss of $1,022,000 in the prior year period.
• Achieved net income of $4,368,000 for the nine months ended September 30, 2025, compared to a net loss of $3,034,000 for the same period in 2024.
• Product revenue increased by 336.2% to $7,084,000 for the three months ended September 30, 2025, and by 77.6% to $11,934,000 for the nine months ended September 30, 2025.
• The company completed the sale of 16 PACHA synthetic products and related assets to R.J. Reynolds Vapor Company for a combined $7.5 million, plus a contingent payment of up to $4.2 million.
• Working capital improved significantly to $3,079,000 as of September 30, 2025, from a deficit of $1,855,000 at December 31, 2024.
• Cash balance increased to $1,150,000 as of September 30, 2025, from $211,000 at December 31, 2024.
• Received a Marketing Denial Order (MDO) from the FDA for certain PMTAs on October 28, 2025, but secured a temporary administrative stay from the Fifth Circuit Court of Appeals on November 10, 2025.
• The Board of Directors approved the winding down and permanent closure of the Don Polly division in October 2025.
• Secured over $6 million in purchase orders at the NACS Show in October 2025, including a record $4.4 million SBX purchase order, with early SBX sales exceeding expectations.

Sentiment

Score: 7

Explanation: The company demonstrated significant financial improvements, moving to profitability and strengthening its balance sheet, largely due to a major asset sale and promising new product line (SBX). However, the 'going concern' warning and ongoing regulatory challenges, including an MDO from the FDA, temper the overall positive sentiment, indicating substantial risks remain.

Positives

• Significant increase in product revenue: 336.2% for the quarter ($7,084,000 vs. $1,624,000) and 77.6% for the nine months ($11,934,000 vs. $6,718,000).
• Transitioned from net losses to net income: $624,000 for the quarter and $4,368,000 for the nine months.
• Substantial improvement in working capital, moving from a $1,855,000 deficit to a $3,079,000 surplus.
• Cash position significantly strengthened to $1,150,000 from $211,000.
• Successful sale of 16 PACHA synthetic products and related assets to R.J. Reynolds Vapor Company for $7.5 million cash, with potential for an additional $4.2 million contingent payment.
• Strong performance of the new SBX Metatine-based disposable vape products, with early sales exceeding expectations and a record $4.4 million single sale.
• Successfully obtained a temporary administrative stay from the Fifth Circuit Court of Appeals regarding the FDA's Marketing Denial Order for certain PMTAs.
• Management voluntarily reduced salaries by 20-50% and implemented headcount reductions to optimize cost structure.
• Secured a 'company friendly' $2 million credit facility with an independent board member to support SBX inventory purchases and growth.

Negatives

• Net cash used in operating activities increased significantly to $6,172,000 for the nine months ended September 30, 2025, from $1,244,000 in the prior year.
• Despite financial improvements, there remains 'substantial doubt about the Company's ability to continue as a going concern'.
• Received a Marketing Denial Order (MDO) from the FDA for certain timely-submitted PMTAs, requiring legal action to maintain market presence for those products.
• The gross profit margin decreased for the nine months ended September 30, 2025, to 24.7% (from 35.0% in 2024), primarily due to lower margins on third-party brands distributed through Don Polly.
• Interest expense increased to $614,000 for the nine months ended September 30, 2025, from $485,000 in the prior year, due to increased outstanding notes payable.
• The Don Polly division, a consolidated variable interest entity, is being wound down and permanently closed, indicating a divestment from a segment of the business.

Risks

• Substantial doubt about the Company's ability to continue as a going concern, requiring additional financing that may not be available on acceptable terms.
• Rapid changes and developments in laws and regulations (federal, state, local) regarding flavored e-cigarettes, nicotine levels, and ENDS products could significantly limit sales or increase compliance costs.
• Risk of FDA denying other pending PMTAs, which would require the company to remove products and cease selling them, absent a court-ordered stay.
• Potential for Congress or the FDA to bestow regulatory control over Metatine, subjecting SBX products to FDA tobacco requirements and premarket authorization.
• Customer concentration risk: Four customers made up more than 36% of net accounts receivable at September 30, 2025.
• Vendor concentration risk: Purchases from three vendors represented 79% of total inventory purchases for the three months ended September 30, 2025.
• Ability to utilize Net Operating Losses (NOLs) and tax credit carryforwards may be limited by ownership changes (Sections 382 and 383 of the Code) or future regulatory changes.
• Litigation or other legal/administrative proceedings, regardless of outcome, could result in substantial cost and diversion of management resources.

Future Outlook

The company intends to begin manufacturing certain products in a US-operated facility in Q4 2025 to meet domestic manufacturing requirements. It plans to vigorously defend its PMTAs against the FDA's Marketing Denial Order and pursue a preliminary injunction. The company is test-marketing Metatine-based e-liquids under the PACHAMAMA PLUS+ trademark and developing a Metatine-based pouch line for late 2025. Management aims to uplist to a national securities exchange once listing requirements are met to increase market visibility, liquidity, and access to capital. The company is also dedicating resources to grow its international market share.

Management Comments

• "Our plans and growth depend on our ability to increase revenues, procure cost-effective financing, and continue our business development efforts."
• "The Company may require additional financing in the future to support the development of new product categories as well as general operations."
• "The Company and its attorneys believe SBX products are not subject to FDA review."
• "We intend to promptly seek a preliminary injunction to remain in effect during the pendency of the litigation, and we plan to vigorously defend our PMTAs and pursue all available legal remedies."
• "Though a very small percentage of our current sales are related to our affected PMTA Products..."
• "Management believes that these initiatives will enhance Charlies competitive position in the marketplace, significantly reduce costs, help accelerate the Companys path to profitability, support business growth, and, ultimately, allow the Company to achieve greater liquidity and visibility through an uplist to a national securities exchange."
• "The Company believes Charlies 650+ PMTAs, as a stand-alone asset, have a monetary value that far exceeds Charlies current market cap."
• "Company executives voluntarily reduced their salaries by 20-50%."
• "Early SBX sales continue to exceed Company expectations."

Industry Context

The vapor products industry is subject to rapid and evolving regulatory changes, including state and federal bans on flavored e-cigarettes and increased FDA scrutiny over nicotine and synthetic nicotine products. The FDA's assertion of authority over synthetic nicotine and its issuance of Marketing Denial Orders (MDOs) create significant market uncertainty. Charlies Holdings is navigating this by developing 'regulatory hedges' through non-nicotine alternative alkaloid products like SBX (Metatine-based) and investing in age-gating technology, similar to initiatives by major competitors like JUUL, Altria, and R.J. Reynolds. The company's sale of PMTA assets to R.J. Reynolds Vapor Company highlights the strategic value of FDA-compliant product portfolios in a consolidating market. The emergence of domestic manufacturing requirements, such as Texas's SB 2024, is also shaping operational strategies.

Comparison to Industry Standards

• Charlies Holdings' focus on full FDA compliance and development of alternative zero-nicotine product lines (Metatine/SBX) positions it differently from many competitors who may not have invested as heavily in regulatory pathways.
• The sale of 16 PACHA synthetic products to R.J. Reynolds Vapor Company for $7.5 million plus contingent payments demonstrates the strategic value of the company's PMTA portfolio, comparable to how larger tobacco companies acquire compliant assets.
• The development of 'age-gating technology' aligns with efforts by industry giants like JUUL Labs, Altria, and R.J. Reynolds, who have also submitted PMTAs for devices with similar age-verification features, indicating a shared industry focus on addressing youth access concerns.
• The company's SBX Disposables were overwhelmingly preferred over Juul tobacco-flavored vapes in a company-sponsored focus group (287 out of 306 participants), suggesting a competitive product offering in the non-nicotine segment.
• The plan to launch a U.S.-filled product line in Q4 2025 directly addresses new domestic manufacturing requirements, such as Texas Senate Bill 2024, a trend that will likely impact all companies operating in states with similar legislation.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal or administrative proceedings as of the filing date, other than the ongoing appeal of the FDA's Marketing Denial Order.
• Filed a motion for a temporary administrative stay with the United States Court of Appeals for the Fifth Circuit on November 5, 2025, regarding the FDA's MDO, which was granted on November 10, 2025.
• Intends to promptly seek a preliminary injunction to remain in effect during the pendency of the litigation and plans to vigorously defend its PMTAs.

Related Party Transactions

• Notes payable to related parties totaled $2,481,000 as of September 30, 2025.
• A $100,000 short-term loan was entered into with President Henry Sicignano III on February 27, 2025, and fully repaid in April 2025.
• Approximately $238,000 of the July 2023 Notes remained outstanding as of September 30, 2025, owed to executives (Ryan Stump, Henry Sicignano III, Keith Stump, Jessica Greenwald) and stockholders (Brandon Stump, Red Beard Holdings LLC, Michael King), with maturity extended to April 28, 2026.
• The August 2022 Loan from COO Ryan Stump for $300,000 was fully repaid on April 28, 2025.
• An additional secured promissory note (August Note) for $2,000,000 was issued to Michael King (independent board member) on August 6, 2025, with a 13% annual interest rate and a one-year term.
• Total rent paid to related parties for the nine months ended September 30, 2025, and 2024 was approximately $207,000 each period, related to the corporate headquarters lease (with Brandon Stump, Ryan Stump, and Keith Stump) and the Williamsville Lease (with Henry Sicignano Jr.).

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance, strategic asset sale, and growth of new product lines (SBX). However, the 'going concern' risk and regulatory uncertainties could lead to volatility and potential loss of investment.
• Employees: Voluntary salary reductions for executives and headcount reductions indicate cost-cutting measures, potentially impacting employee morale or job security. Bonuses awarded to key employees suggest performance-based incentives.
• Customers: Introduction of new SBX Metatine-based products offers alternative options, while the MDO on certain PMTA products could lead to product unavailability if legal challenges fail.
• Suppliers: Vendor concentration indicates reliance on a few key suppliers, which could pose supply chain risks. The Chemular note settlement and warrant exercise for vendor credit demonstrate efforts to manage supplier relationships.
• Creditors: Improved working capital and cash position, along with the $2 million credit facility, enhance the company's ability to meet short-term obligations, but the 'going concern' warning still signals elevated risk.

Next Steps

• Promptly seek a preliminary injunction to keep affected PMTA products on the market during litigation against the FDA's Marketing Denial Order.
• Vigorously defend PMTAs and pursue all available legal remedies regarding the FDA's MDO.
• Begin manufacturing certain products in a Company-operated facility in the United States in Q4 2025 to meet domestic requirements.
• Continue test-marketing Metatine-based e-liquids under the PACHAMAMA PLUS+ trademark.
• Develop a Metatine-based pouch line, potentially ready for market in late 2025.
• Develop new distribution partnerships to grow the nicotine disposable business in 2025-2026.
• Continue to develop intellectual property around and seek strategic partnerships for age-gating technology.
• Uplist from the OTCQB exchange to a national securities exchange as soon as listing requirements are met.
• Dedicated additional resources to efforts focused on growing market share internationally.

Key Dates

Recommendation

Charlies Holdings, Inc. presents a mixed bag for investors. The significant financial turnaround, driven by the $7.5 million asset sale and the promising early success of the SBX Metatine product line, is a strong positive. The company has moved from a net loss to a net income and substantially improved its working capital and cash position. However, the persistent 'substantial doubt about the Company's ability to continue as a going concern' cannot be overlooked, indicating fundamental operational challenges despite the recent cash infusion. The ongoing regulatory battle with the FDA over PMTAs, even with a temporary stay, introduces considerable uncertainty. While the SBX product line offers a potential 'regulatory hedge,' its long-term regulatory status is not guaranteed. The high net cash used in operating activities suggests that the company's core operations are still burning cash, making the asset sale a critical, but potentially one-time, lifeline. Given the strong upside potential from SBX and the improved balance sheet, but balanced against significant regulatory and operational risks, a 'hold' recommendation is appropriate. Investors should monitor the FDA litigation, SBX sales trajectory, and the company's ability to achieve sustainable operational profitability without relying on asset sales.

Keywords

Vapor Products, E-cigarettes, FDA Regulation, PMTA, Metatine, SBX, Nicotine Alternative, Asset Sale, Going Concern, Financial Results, Q3 2025, Charlies Holdings